Market incentives, human lives, and AIDS vaccines

Social Science and Medicine

Volumn 64, Issue 5, 2007, Pages 1042-1056

  Craddock, Susan ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Africa; AIDS vaccine; Biomedical research; Medical capitalism; Pharmaceutical; USA

Indexed keywords

ALVAC; ANTIRETROVIRUS AGENT; AVAC; GENERIC DRUG; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAPITALISM; DRUG DEVELOPMENT; EPIDEMIC; INCENTIVE; PHARMACEUTICAL INDUSTRY; VACCINATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLADISTICS; CLINICAL TRIAL; COOPERATION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EPIDEMIC; FUNDING; HEART FAILURE; HUMAN; IMMUNOGENICITY; LOWEST INCOME GROUP; MARKET; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MONEY; ORGANIZATION; PATENT; POLITICAL SYSTEM; PROFIT; RISK REDUCTION; VACCINE PRODUCTION;

AFRICA; AIDS VACCINES; BIOMEDICAL RESEARCH; CLINICAL TRIALS; DRUG INDUSTRY; HEALTH CARE SECTOR; HIV INFECTIONS; HUMANS; POVERTY AREAS; PUBLIC POLICY; UNITED NATIONS; WORLD HEALTH;

AFRICA; EAST AFRICA; KENYA; NORTH AMERICA; SOUTH AFRICA; SOUTHERN AFRICA; SUB-SAHARAN AFRICA; UNITED STATES;

EID: 33846829611     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2006.10.006     Document Type: Article

References (66)

1. Adams, C. (2003). Personal communication, 14 October.
2. Agamben G. Homo sacer: Sovereigh power and bare life. Translated by Daniel Heller-Roazen (1998), Stanford University Press, Palo Alto
3. AIDS Alert. (2003). VaxGen vaccine trial fails the test but may offer insights; presentation of data draws criticism as 'premature'. 18(4), 41-45.
4. AIDS Vaccine Advocacy Coalition (AVAC). (2004). Report. www.avac.org.
5. Angell M. The truth about the drug companies: How they Deceive us and what to do about it (2004), Random House, New York
6. Beloqui J., Chokevivat V., and Collins C. HIV vaccine research and human rights: examples from three countries planning efficacy trials. Health and Human Rights 3 1 (1998) 38-58
7. Berger, J., (2004). AIDS Law Project, South Africa. In Presentation at the XVth international AIDS conference, Bangkok, Thailand, 13 August.
8. Bok D. Universities in the marketplace: The commercialization of higher education (2003), Princeton University Press, Princeton, NJ
9. Bourdieu P. Acts of resistance against the tyranny of the market (1998), The New Press, New York
10. Brown, D. (2003). AIDS Fund in need of $1 billion to support grant applications. The Washington Post, 8 May, A02.
11. Burton D., Desrosiers R., Doms R., Feinberg M., Gallo R., Hahn B., et al. A sound rationale needed for Phase III HIV-1 vaccine trials. Science 303 (2004) 316
12. Chadwick, J. (2003). Personal communication, 8 September.
13. Chou I., and Jayaraman K. India, Japan launch HIV vaccines to match local strains. Nature Medicine 10 3 (2004) 215
14. ClinicalTrials.gov. (2004). Information on clinical trials and human research studies. National Library of Medicine: clinicaltrials.gov.
15. Cohen J. Shots in the dark: The wayward search for an AIDS vaccine (2001), W.W. Norton, New York
16. Cook, C. (2003). Personal communication. 26 August.
17. Desrosiers R. Prospects for an AIDS vaccine. Nature Medicine 10 3 (2004) 221-223
18. Falk R. Human rights horizons: The pursuit of justice in a globalizing world (2000), Routledge, New York
19. Farmer P. Infections and inequalities: The modern plagues (2001), University of California, Berkeley
20. Farmer P. Pathologies of power: Health, human rights, and the new war on the poor (2004), University of California, Berkeley
21. Galbraith, J.K. (2002). A perfect crime: Inequality in the age of globalization. Daedalus, Winter.
22. Gates Foundation. (2004). www.gatesfoundation.org/StoryGallery/GlobalHealth/SGGHIAVI-011011.htm (last visited 1 June).
23. Gelijns A., and Their S. Medical innovation and institutional interdependence: Rethinking university-industry connections. JAMA 281 1 (2002) 72-77
24. Gibson-Graham J.-K. The end of capitalism (as we knew it): A feminist critique of political economy (1996), Blackwell, Oxford
25. Glassman J. From Seattle (and Ubon) to Bangkok: The scales of resistance to corporate globalization. Environment and Planning D: Society and Space 19 (2001) 513-533
26. Goozner M. The $800 million pill: The truth behind the cost of new drugs (2004), University of California, Berkeley
27. Harvey D. Spaces of hope (2000), University of California, Berkeley
28. Heywood M. Drug access, patents and global health: 'Chaffed and waxed sufficient'. Third World Quarterly 23 2 (2002) 217-231
29. HIV/AIDS Vaccine Ethics Group, (HAVEG). (2003). Personal communication. 26 October, University of Natal, South Africa.
30. International AIDS Vaccine Initiative (IAVI). (2004). Highlights in AIDS vaccine research-2003. www.iavi.org.
31. Ismail, M.A. (2005). Prescription for power: Drug makers' lobbying army ensures their legislative dominance. Center for Public Integrity, 28 April. www.publicintegrity.org/lobby/report.aspx?aid.
32. Jack, A., & Williams, F. (2005). Patent pools spread ripples in research. Financial Times, May 20.
33. Kahn J. Getting the numbers right: Statistical mischief and racial profiling in heart failure research. Perspectives in Biology and Medicine 46 4 (2003)
34. In: Kalipeni E., Craddock S., Oppong J., and Ghosh J. (Eds). HIV and AIDS in Africa: Beyond epidemiology (2004), Blackwell, Boston
35. Klausner R.D., Fauci A.S., Corey L., Nabel G.J., Gayle H., Berkley S., et al. The need for a global HIV vaccine enterprise. Science 300 5628 (2003) 2036-2039
36. Krimsky S., and Nadar R. Science in the private interest: Has the lure of profits corrupted biomedical research? (2003), Rowman & Littlefield, New York
37. In: Lerner W. (Ed). Neoliberalism? Guest editorial. Environment and Planning D: Society and Space 21 (2003) 509-512
38. Loff B., and Heywood M. Patents on drugs: Manufacturing scarcity or advancing health?. Journal of Law, Medicine & Ethics 30 (2002) 621-631
39. McKinnell, H. (2004). CEO, Pfizer Phamraceutical Corporation. In Presentation at the XVth international AIDS conference, Bangkok, Thailand, 13 August.
40. Mercury News. (2004). UC Santa Barbara patent gift to aid parasite fight. 24 February.
41. Mikhail P. Hopkins V. CellPro: An illustration that patenting and exclusive licensing of fundamental science is not always in the public interest. Harvard Journal of Law and Technology 13 2 (2000) 375-394
42. Mitchell T. Rule of experts: Egypt, techno-politics, modernity (2002), University of California, Berkeley
43. Mitka M. Critics bash HIV vaccine trial analysis. JAMA 289 12 (2003) 1491
44. Muraskin W. The politics of international health: The children's vaccine initiative and the struggle to develop vaccines for the third world (1998), SUNY Press, New York
45. National Institute of Allergies and Infectious Diseases. (2003). Challenges in developing AIDS vaccines. www.niaid.nih.gov/daids/vaccine/challenges.htm.
46. Nelson K. United Nations panel warns of slow progress against HIV/AIDS. The Lancet 362 (2003) 1045
47. Pollack, A., (2005). Open-source practices for biotechnology. New York Times 10 February, www.nytimes.com/2002/02/10/technology/10gene.html.
48. Public Campaign Action Fund. (2004). Buying a law: Big pharma's big money and the Bush medicare plan. January 15. www.pcactionfund.org.
49. Rajkumar, R. (2005). CAFTA will hurt people with HIV. The Boston Globe, 26 May A18.
50. Rogers, F. (2003). Personal communication, 10 September.
51. Schoofs, M. (2000). Glaxo attempts to block access to generic drugs in Ghana. Wall Street Journal, 1 December.
52. Schultz, C. (2002). Personal communication, 16 October.
53. Sen A. Development as freedom (1999), Anchor Books, New York
54. 't Hoen, E. (2003). Personal communication, 2 April.
55. 't Hoen E.F.M. The responsibility of research universities to promote access to essential medicines. Yale Journal of Health Policy, Law, and Ethics III 2 (2003) 293-300
56. Thaiwait, N. (2004). ALVAC vaccine community outreach member. In Presentation at the XVth international AIDS conference, Bangkok, Thailand, 14 August.
57. Thomas C. Trade policy and the politics of access to drugs. Third World Quarterly 23 2 (2002) 251-264
58. Thomas P. Big shot: passion, politics, and the struggle for an AIDS vaccine (2001), Public Affairs, New York
59. Trinvuthipong C. Thailand's prime-boost HIV vaccine Phase III. Science 303 303 (2004) 954
60. UNAIDS. World epidemic update (2003), World Health Organization, Geneva
61. UNAIDS (2004). World epidemic update. Geneva: World Health Organization.
62. Vaccine Weekly. AIDSVAX developer releases third-quarter financial results. Staff Report December 18 (2002) 9
63. Waters, J. (2003). Personal communication, 6 November.
64. WHO. A commitment to action for expanded access to HIV/AIDS treatment. International HIV treatment access coalition (2002), World Health Organization, Geneva
65. Wolf H. Letter in response to Klausner and colleagues. Science 303 (2004) 1295-1296
66. Zinkernagel R. Letter in response to Klausner and colleagues. Science 303 (2004) 1294-1295